WHO warns against dengue vaccine risks
Fresh concerns about the efficacy of the world’s first ever Dengue vaccine has come to light as the World Health Organisation (WHO) noted that there is an urgent need to describe the potential risks of the vaccine.
Therefore, WHO has advised the countries planning to use the vaccine to screen the population before vaccination. It has strictly directed the countries to vaccinate only seropositive (tested positive for dengue) individuals.
Dengvaxia (CYD-TDV), the vaccine in question is produced by the Pharmaceutical giant Sanofi Pasteur. The Strategic Advisory Group of Experts (SAGE) formulated by WHO is examining the concerns caused by the vaccine.
SAGE has also looked at the population seroprevalence criteria (percentage of population affected by dengue) to ensure that only those affected by dengue get the jab.